Fetal bovine serum, a by-product of the beef industry, is a critical raw material for animal health, biotechnology, diagnostic, and the pharmaceutical industry along with several research areas, as it is a safe and effective growth medium for most of the experimental procedures. Blood from cattle fetus is centrifuged to remove the RBCs (red blood cells). The fraction that remains after natural coagulation of blood is fetal bovine serum. In vitro cell cultures are grown in a controlled environment with optimum concentration of nutrients. Fetal bovine serum boosts cell cycle and cell metabolism and is an important component of the nutrient media which comprises of vitamins, hormones, and nutrients.
The global fetal bovine serum (FBS) market is undergoing unprecedented dynamics. Sterile filtered serum with low concentration of endotoxins having broad performance irrespective of the cell lines has considerable demand in the global fetal bovine serum market. The global average cost of fetal bovine serum has increased exponentially in the past few years as the availability of FBS is dependent on environmental conditions. The FBS industry is seeing a product shortage due to adverse environmental conditions, globally increased beef and dairy demand that has reduced total cattle herd population to the lowest in 60 years. This along with mergers and product recalls has resulted in reducing product availability and increased product costs. However, fetal bovine serum is still a major ingredient of nutrient medium for cell cultures, as scientists have not yet discovered any replacement for FBS in large volumes.
View Report –
The global fetal bovine serum market has been segmented based on region of origin, specialty product type, application, and end-user. In terms of region of origin, the market has been categorized into North America, South America, Australia, New Zealand, and others. Fetal bovine serum from regions with low prevalence rates of bovine spongiform encephalopathy (BSE) have greater demand in the global fetal bovine serum market. In terms of specialty product type, the global fetal bovine serum market has been segmented into charcoal stripped FBS, chromatographic purified for low antibody FBS, dialyzed FBS, stem cell qualified FBS, exosome depleted FBS, and others. Stem cell qualified FBS is further divided into embryonic stem cells qualified FBS, mesenchymal stem cell-qualified FBS, and others. Based on application, the global fetal bovine serum market has been segmented into antibody production, veterinary applications, cell culture maintenance, exosome studies, immunoassays, and others. The immunoassays segment has been sub-segmented into radiolabeling assays, insulin assay methods, and others. In terms of end-user, the global fetal bovine serum market has been categorized into research/academic institutes, diagnostic labs, cell banks (stem cell banks, tumor cell banks, blood bank, etc.), biopharmaceutical companies, and others.
An emerging trend in the global fetal bovine serum market is a shift from animal derivatives to human serum, as it is cost-effective and easy for regulatory approvals. Preference for human serum is higher as compared to animal derived serum, especially for new cell line research. Intense quality analysis for sterility, performance, low antibody titer, mycoplasmas and endotoxins along with intricate manufacturing process that retains the nutrients in the fetal bovine serum needed for cell growth augment the global fetal bovine serum market.
In terms of region, the global fetal bovine serum market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is expected to show continual growth owing to low labor cost, less capital investment for manufacturing of fetal bovine serum, rising demand for Australia origin fetal bovine serum, and increasing cell maintenance banks and specialty research institutes. North America is expected to dominate the global fetal bovine serum market as new and technologically advanced products are first introduced in the country, significant investments in research and development, and increasing demand from research institutes.
Key players in the global fetal bovine serum market are Sigma-Aldrich Co. LLC., GE Healthcare, Thermo Fisher Scientific Inc., TCS Biosciences Ltd., HiMedia Laboratories, Atlanta Biologicals, Inc., PAN-Biotech, Rocky Mountain Biologicals, Bovogen Biologicals Pty Ltd., and Tissue Culture Biologicals, among others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
Market segments and sub-segments
Market trends and dynamics
Supply and demand
Value chain and stakeholder analysis
The regional analysis covers:
North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
Eastern Europe (Poland and Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
Middle East and Africa (GCC, Southern Africa, and North Africa)
Request a brochure of this report to know what opportunities will emerge in the rapidly evolving Fetal Bovine Serum Market during 2016- 2024
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453